Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01965782 · ClinicalTrials.gov registry record · Phase 1
A Study of [14C]-LY3023703 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01965782 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT01965782, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This type of study is called a radiolabeled study. For this study, LY3023703 (study drug) has been specially prepared to contain radiolabeled carbon \[14C\]. \[14C\] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered to healthy men. Information about any side effects that may occur will also be collected. This study will last up to 15 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.
Interventions
- DRUG [^14C]-LY3023703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-10 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01965782
The ClinicalTrials.gov registry entry for NCT01965782 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [^14C]-LY3023703 is the first listed.
NCT01965782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01965782 about?
NCT01965782 is a clinical study titled "A Study of [14C]-LY3023703 in Healthy Participants". This type of study is called a radiolabeled study. For this study, LY3023703 (study drug) has been specially prepared to contain radiolabeled carbon \[14C\]. \[14C\] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, ur...
What is the current status of trial NCT01965782?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-10. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01965782?
The interventions under investigation include: [^14C]-LY3023703 (DRUG).
Who is sponsoring clinical trial NCT01965782?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.